Full Archive
Metabolic vulnerabilities in pleural mesothelioma
Oncogenesis 2026 May 20 [Link] Sílvia Plans-Marin, Cristina Muñoz-Pinedo, Ernest Nadal Abstract Mesothelioma is a rare tumour of mesothelial origin that is often diagnosed at advanced stages. Despite recent approval of immunotherapy, the prognosis of mesothelioma remains dismal. Growing evidence links tumour metabolism to the molecular mechanisms driving mesothelioma’s aggressiveness, therapeutic resistance and poor outcomes.…
Read MoreThe Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreA case of diffuse malignant peritoneal mesothelioma: case report and literature review
Irish Journal of Medical Science 2026 May 19 [Link] Qian Zhao, Kangwei Xiong, Qiaoyun Wang, Lijiu Zhang Abstract Introduction: Diffuse malignant peritoneal mesothelioma (DMPM) is a very rare and life-threateningmalignant tumor. Case: We present a report of a rare case of a 70-year-old female patient with emaciation and poor appetite as manifestations. The characteristics of…
Read MoreMolecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas
Translational Oncology 2026 July [Link] Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb Abstract Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in…
Read MoreMolecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas
Translational Oncology 2026 July [Link] Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb Abstract Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in…
Read MoreCooperative response loops enhanced by histamine signaling during tumor-neutrophil crosstalk in pleural mesothelioma
Cell Reports 2026 May 26 [Link] Kuniyo Sueyoshi, Miwako Kakiuchi, Daisuke Komura, Hiroto Katoh, Asami Yamamoto, Susumu Kirimura, Iichiroh Onishi, Ayaka Asakawa, Hironori Ishibashi, Kenichi Ohashi, Kenichi Okubo, Shumpei Ishikawa Abstract Pleural mesothelioma (PM) is an aggressive malignancy marked by substantial intratumor heterogeneity. A subset enriched in neutrophils correlates with poor prognosis, yet the underlying…
Read MoreQuantitative MRI-Based T Category in Pleural Mesothelioma: Analysis of a Large Real-World Cohort
Academic Radiology 2026 May 15 [Link] Ritu R Gill, William G Richards, Emanuele Mazzola, Beow Y Yeap, Raphael Bueno Abstract Rationale and objectives: Accurate clinical staging in pleural mesothelioma (PM) is limited by the subjectivity of conventional imaging assessment, which introduces inter- and intraobserver variability. Tumor volume, pleural thickness and diaphragmatic thickness measurements individually prognostic…
Read MoreRethinking continuity in general practice for people with incurable illness: a qualitative case study of mesothelioma
The British Journal of General Practice 2026 May 14 [Link] Emilie Couchman, Steph Ejegi-Memeh, Sarah Mitchell, Clare Gardiner Abstract Background: Continuity in general practice has clear benefits but is difficult to achieve. Existing research has identified groups of individuals who may especially benefit from continuity, such as those with a terminal condition. Mesothelioma is an…
Read MoreClinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings
Journal of Clinical Pathology 2026 June 18 [Link] Dina Moustafa Thabit, Dalia M Thabet Abstract Aims: Distinguishing epithelioid malignant mesothelioma (EMM) from poorly differentiated lung adenocarcinoma (PD-LUAD) remains challenging, particularly when 21.7% of PD-LUADs lack lineage-specific markers (thyroid transcription factor-1 (TTF-1)/Napsin A), creating a diagnostic blind spot. While GATA-binding protein 3 (GATA3) is established in…
Read MoreDiagnostic Yield of Malignant Pleural Effusion in Various Primary and Metastatic Cancers: Insights Across Cancer Subtypes
Pulmonary Medicine 2026 [Link] Santosh Basyal, Antony D Rawindraraj, Rahul Parajuli, Shardul Bhattarai, Laxman Wagle, Kritick Bhandari, Vikas Pathak Abstract Objective/background: Pleural fluid cytology remains a cornerstone in diagnosing malignant pleural effusions (MPEs); however, its diagnostic yield varies considerably across cancer subtypes. This study is aimed at evaluating the diagnostic performance of cytology stratified by…
Read More
Skip to content